Mechanism of Fei-Xian Formula in the Treatment of Pulmonary Fibrosis on the Basis of Network Pharmacology Analysis Combined with Molecular Docking Validation

Abstract

Objective. This study aimed to clarify the mechanism of Fei-Xian formula (FXF) in the treatment of pulmonary fibrosis based on network pharmacology analysis combined with molecular docking validation. Methods. Firstly, ingredients in FXF with pharmacological activities, together with specific targets, were identified based on the BATMA-TCM and TCMSP databases. Then, targets associated with pulmonary fibrosis, which included pathogenic targets as well as those known therapeutic targets, were screened against the CTD, TTD, GeneCards, and DisGeNet databases. Later, Cytoscape was employed to construct a candidate component-target network of FXF for treating pulmonary fibrosis. In addition, for nodes within the as-constructed network, topological parameters were calculated using CytoHubba plug-in, and the degree value (twice as high as the median degree value for all the nodes) was adopted to select core components as well as core targets of FXF for treating pulmonary fibrosis, which were subsequently utilized for constructing the core network. Furthermore, molecular docking study was carried out on those core active ingredients together with the core targets using AutoDock Vina for verifying results of network pharmacology analysis. At last, OmicShare was employed for enrichment analysis of the core targets. Results. Altogether 12 active ingredients along with 13 core targets were identified from our constructed core component-target network of FXF for the treatment of pulmonary fibrosis. As revealed by enrichment analysis, the 13 core targets mostly concentrated in regulating biological functions, like response to external stimulus (from oxidative stress, radiation, UV, chemical substances, and virus infection), apoptosis, cell cycle, aging, immune process, and protein metabolism. In addition, several pathways, like IL-17, AGE-RAGE, TNF, HIF-1, PI3K-AKT, NOD-like receptor, T/B cell receptor, and virus infection-related pathways, exerted vital parts in FXF in the treatment of pulmonary fibrosis. Conclusions. FXF can treat pulmonary fibrosis through a “multicomponent, multitarget, and multipathway” mean. Findings in this work lay foundation for further exploration of the FXF mechanism in the treatment of pulmonary fibrosis.

Mechanism of salidroside against coronary artery disease by network pharmacology analysis

“…Thereafter, the ligand was integrated into the target proteins in a semi-flexible manner, resulting in a total of 20 conformations. The most affinal conformation was chosen to be the eventual docking conformation [ 23 ]. Pymol2.4 and Ligplot2.2 were used to further analyze their binding patterns, binding affinity and critical interactions.…”

Exploration of the Pharmacological Mechanism of Bufei Nashen Pill in Treating Chronic Obstructive Pulmonary Disease Using Network Pharmacology Integrated Molecular Docking

“…The most important biological process (BP), cellular component (CC 2 ), molecular function (MF), and KEGG pathway results were screened and stored, with a threshold of P <0.01 and FDR < 0.01. An online drawing website Omicshare Tools (https://www.omicshare.com/tools/Home/Soft/getsoft 25 ) was used to visualize the results.…”

“…The intersection targets between the COPD-related targets and active compounds were retained by using a Venn tool (https://bioinfogp.cnb.csic.es/tools/venny/). 25 These targets were considered as potential therapeutic targets of BFNSP for COPD patients. A “Drug-Ingredients-Potential Targets” network was constructed by Cytoscape 3.3.0 software (https://cytoscape.org/download.html).…”

Network pharmacology and in silico approaches to uncover multitargeted mechanism of action of Zingiber zerumbet rhizomes for the treatment of idiopathic pulmonary fibrosis

“…5 Hence, there is a need to discover new drugs for IPF and the most recent trends in literature for herbal products with multitargeted approaches. [6][7][8] The network pharmacology tools are used to interpret Chinese traditional drugs for their mechanistic activity in IPF, such as Fei-Xian Formula, 9 Qingfei oral liquid, 10 Baofeikang Granules, 11 Astragalus Polysaccharide, 12 Isorhynchophylline, 13 and Platycodon grandiflorum. 14 The major pharmacological activity of these drugs is inhibiting TGF-β, multi-targeted molecular modulation of inflammation and antioxidant.…”